259 related articles for article (PubMed ID: 24952364)
1. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
[TBL] [Abstract][Full Text] [Related]
2. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer.
Vermassen T; Van Praet C; Lumen N; Decaestecker K; Vanderschaeghe D; Callewaert N; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Prostate; 2015 Feb; 75(3):314-22. PubMed ID: 25358590
[TBL] [Abstract][Full Text] [Related]
3. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
4. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
5. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
6. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
7. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
8. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
[TBL] [Abstract][Full Text] [Related]
10. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
12. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
13. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
14. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
Semjonow A; Hamm M; Rathert P
Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
[TBL] [Abstract][Full Text] [Related]
15. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
16. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
17. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
Zenimoto M; Kita M; Arai T; Murayama T; Mori M
Rinsho Byori; 2003 Oct; 51(10):969-73. PubMed ID: 14653195
[TBL] [Abstract][Full Text] [Related]
18. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
19. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
Su HW; Li Y; Xu P
Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]